Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.73 |
| ▸ | TFPI | P10646 | 4/20 | 0.68 |
| ▸ | RAMP3 | O60896 | 4/20 | 0.68 |
| ▸ | CALCR | P30988 | 4/20 | 0.68 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.66 |
| ▸ | NPY2R | P49146 | 7/20 | 0.65 |
| ▸ | NPY4R | P50391 | 7/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.65 |
| ▸ | NPY1R | P25929 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29210101 | 1.00 | CALCA (0.73) | CALCATFPIRAMP3CALCRCXCR4 | |
| SCHEMBL29459653 | 0.94 | CALCA (0.73) | CALCATFPIRAMP3CALCRNPY2R | |
| SCHEMBL29360080 | 0.94 | CALCA (0.73) | CALCATFPIRAMP3CALCRNPY2R | |
| SCHEMBL31060662 | 0.94 | CALCA (0.82) | CALCATFPIRAMP3CALCRNPY2R | |
| SCHEMBL29783625 | 0.93 | CALCR (0.65) | CALCATFPIRAMP3CALCRCXCR4 | |
| SCHEMBL31251982 | 0.89 | CALCA (0.90) | CALCATFPICXCR4NPY2RNPY4R | |
| SCHEMBL238214 | 0.87 | NPY2R (0.69) | TFPIRAMP3CALCRCXCR4NPY2R | |
| SCHEMBL29743043 | 0.87 | CALCA (0.65) | CALCATFPIRAMP3CALCRNPY2R | |
| SCHEMBL268329 | 0.86 | NPY2R (0.73) | TFPIRAMP3CALCRCXCR4NPY2R | |
| SCHEMBL29783636 | 0.86 | CALCR (0.73) | TFPIRAMP3CALCRNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630614-B2 | Treatment of headache using anti-CGRP antibodies hereof | H. LUNDBECK A/S (DK) | 2026-05-19 | — | — | US | disclosed |
| US-20260125454-A1 | ANTI-CGRP ANTIBODY AND USE | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2026-05-07 | — | — | US | disclosed |
| EP-4731664-A1 | COMBINATIONAL TREATMENT | H. Lundbeck A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-20260055168-A1 | TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2026-02-26 | — | — | US | disclosed |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H LUNDBECK AS (DK) | 2026-01-01 | — | — | US | disclosed |
| WO-2025262247-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | H. LUNDBECK A/S (DK) | 2025-12-26 | — | — | WO | disclosed |
| US-20250368726-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2025-12-04 | — | — | US | disclosed |
| US-20250368727-A1 | ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2025-12-04 | — | — | US | disclosed |
| US-12391749-B2 | Acute treatment and rapid treatment of headache using anti-CGRP antibodies | H. LUNDBECK A/S (DK) | 2025-08-19 | — | — | US | disclosed |
| US-12384837-B2 | Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies | H. LUNDBECK A/S (DK) | 2025-08-12 | — | — | US | disclosed |
| US-20220340633-A1 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | ADEPTHERA LLC | 2022-10-27 | — | — | US | disclosed |
| US-20220324935-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2022-10-13 | — | — | US | disclosed |
| US-20220251178-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIESHEREOF | H. LUNDBECK A/S (DK) | 2022-08-11 | — | — | US | disclosed |
| US-11390657-B2 | Peptide analogs | ADEPTHERA LLC (US) | 2022-07-19 | — | — | US | disclosed |
| US-11325967-B2 | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers | H. LUNDBECK A/S (DK) | 2022-05-10 | — | — | US | disclosed |
| CN-108359008-B | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments for the treatment or prevention of chronic and acute forms of diarrhea | H.伦德贝克公司 | 2022-03-29 | — | — | CN | disclosed |
| CN-108373502-B | anti-CGRP compositions and uses thereof | H.伦德贝克公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3962522-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H. Lundbeck A/S (DK) | 2022-03-09 | — | — | EP | disclosed |
| EP-3016684-B1 | REGULATION OF GLUCOSE METABOLISM USING ANTI-CGRP ANTIBODIES | H LUNDBECK AS (DK) | 2022-02-23 | — | — | EP | disclosed |
| US-20220023389-A1 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | UNIVERSITY OF COPENHAGEN (DK) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055168-A1 | TREATMENT OF MOST BOTHERSOME SYMPTOM (MBS) ASSOCIATED WITH MIGRAINE USING ANTI-CGRP ANTIBODIES | IGLV6-57, CALCB, CALCA | CALCA 3/4885TFPI 710/4885RAMP3 280/4885 |
| US-20220340633-A1 | SUPERAGONIST POLYPEPTIDE ANALOGS OF ADRENOMEDULLIN AND INTERMEDIN PEPTIDE HORMONES | RAMP1, CALCRL, RAMP3 | CALCA 11/4885TFPI 1913/4885RAMP3 3/4885 |
| US-20220324935-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | CALCA 26/4885TFPI 2587/4885RAMP3 3/4885 |
| US-20260001942-A1 | TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO | CDR2, OPRL1, TPH1 | CALCA 27/4885TFPI 2246/4885RAMP3 192/4885 |
| US-20260125454-A1 | ANTI-CGRP ANTIBODY AND USE | NPY1R, NPY2R, NPY5R | CALCA 55/4885TFPI 3520/4885RAMP3 320/4885 |
| US-20220023389-A1 | VASODILATORS FOR USE IN THE TREATMENT OF A RETINAL ISCHEMIC DISORDER | EDNRB, EDNRA, VIPR1 | CALCA 14/4885TFPI 1488/4885RAMP3 200/4885 |
| US-11390657-B2 | Peptide analogs | RAMP1, RAMP3, RAMP2 | CALCA 49/4885TFPI 2625/4885RAMP3 2/4885 |
| US-12630614-B2 | Treatment of headache using anti-CGRP antibodies hereof | CALCB, CALCA, CALCRL | CALCA 2/4885TFPI 239/4885RAMP3 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.